Ph.D., CEO, sequence bio
Tyler Wish is the cofounder and CEO of Sequence Bio, a data-driven precision medicine company based in Newfoundland. The company is leading a large-scale initiative designed to deliver precision medicine in Newfoundland and to enable therapeutic discovery. Tyler is a trained genetic epidemiologist with a background in population-based research, human genetics and drug discovery. Prior to Sequence, he was Founder & President of Research Avenue, a niche contract research company that provided outsourced development services to healthcare and life-science companies. Tyler holds a BSc (Chemistry) from the University of Victoria and a PhD (Medicine) from Memorial University of Newfoundland.